Current head and neck research projects


Pawan Kumar, MS, PhD
  • Delineating the role of IL-6 in head and neck cancer progression
  • Identifying novel therapeutic targets for the treatment of head and neck cancers
  • Understanding the role of tumor-associated andothelial cells in promoting tumor metastasis
  • Identifying microRNA dysregulation and studying their role in head and neck cancer progression
Quintin Pan, PhD  
  • Cancer initiating cells and treatment resistance total project
  • Role of p300 in HPV-positive head and neck cancer
  • p53/Rb reactivation modulators for HPV-positive head and neck cancer
  • Bcl-2 as a biomarker for prognosis and therapy of head and neck cancer
  • Use of Vorinostat for definitive treatment of advanced stage oropharyngeal squamous cell carcinoma
Research Grants

Research Grants

Current Research Grants

Sponsor: NIH/NCI SAIC
PI: Jas Lang, PhD
Title: Frederick Cancer Genome Atlas Project (TCGA) BOA 13XS121
Period: 03/26/2013 - present
Goal: The goal of this study is to function as a Tissue Source Site (TSS) to process and provide specimens of head and neck squamous cell carcinoma and matched blood samples for the TCGA project.
   
Sponsor: NIH/NCI-R01CA193590
PI: Quintin Pan, PhD
Title: Cancer Initiating Cells and Treatment Resistance Total Project
Period: 04/08/2015 - 03/31/2020
   
Sponsor: NIH/NIDCR-R01DE023555
PI: Quintin Pan, PhD
Title: Role of p300 in HPV-Positive Head and Neck Cancer     
Period: 05/06/2015 - 04/30/2020
   
Sponsor: NIH/NIGMS-R01GM117921
Co-PI: Quintin Pan, PhD
Title: p53/Rb Reactivation Modulators for HPV-Positive Head and Neck Cancer
Period: 2/01/2016 - 1/31/2020
   
Sponsor: NIH/NIDCR-R01DE022087
Co-PI: Quintin Pan, PhD
Title: Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer
Period: 7/01/2011 - 4/30/2017
   
Sponsor: National Comprehensive Cancer Network
Co-PI: Quintin Pan, PhD
Title: Use of Vorinostat for Definitive Treatment of Advanced Stage Oropharyngeal Squamous Cell Carcinoma             
Period: 02/01/10 - 05/31/16

Clinical Trials for Head and Neck

Phase III Randomized, Open-Label, Multicenter, Global Study of MEDI4736 Alone or in Combination With Tremelimumab vs. Standard of Care in the Treatment of First-Line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
(OSU-15210) Maura Gillison, MD, PhD

Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
(OSU-16120) Maura Gillison, MD, PhD

Randomized, Phase III Trial of Cisplatin-Based Chemotherapy (CRT) +/- Nivolumab (ANTI-PD-1) in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (with Phase I Lead in)
(RTOG-3504) Maura Gillison, MD, PhD

Open-Label, Randomized, Two-Arm Phase III Study of Nivolumab in Combination With Ipilimumab vs. Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
(OSU-16134) Maura Gillison, MD, PhD

Open-Label, Multicenter Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
(OSU-16147) Maura Gillison, MD, PhD

Past Head and Neck Research Grants

  • Use of Vorinostat for Definitive Treatment of Advanced Stage Oropharyngeal Squamous Cell Carcinoma
    PI: Ted Teknos, MD
    2010 - 2014
    National Comprehensive Cancer Network

  • Role of Tumor-Associated Endothelial Cells in Chaperoning Tumor Cells
    PI: Pawan Kumar, MS, PhD
    07/02/2014 - 06/30/2016
    NIH/NCI

  • James Rocco, MD, PhD
    07/01/2011 - 04/30/2016
    NIDCR/NCI
    R01DE022087-01

    BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer
    The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).

  • James Rocco, MD, PhD
    07/01/2011 - 04/30/2016
    NIDCR/NCI
    R01DE022087-01

    BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer
    The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).
Publications

Publications

Pawan Kumar, MS, PhD

Kumar B., Yadav A., Brown V.N., Zhao S., Cipolla M.J., Wakely P.E., Yan F., Schmitt A.C., Baiocchi R.A., Teknos T.N., Old M., and Kumar P*. "High expression of PRMT5 and Cyclin D1 predicts poor outcome in oropharyngeal squamous cell carcinoma and is inversely associated with p16 status. 2017, Oncotarget, doi: 10.18632/oncotarget.14682

Yadav A., Kumar B., Teknos T.N. and Kumar P*. Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer. 2016, Oncotarget, DOI: 10.18632/oncotarget.11464

McMullen K, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: A review. World J Otorhinolaryngology Head Neck Surg. 2016 Jun;2(2): 109-116

Kumar B, Cipolla M, Brown N, Kang SY, Dziegielewski PT, Durmus K, Ozer E, Old MO, Agrawal A, Carrau RL, Schuller DE, Leon M, Pan Q, Kumar P, Wood V, Burgers J, Wakely P, and Teknos TN. Surgical management of oropharyngeal squamous cell carcinoma: survival and functional outcomes. Head Neck. 2016 Apr;38 Suppl 1:E1794-802. PubMed PMID: 26694981

Kumar B, Brown N, Swanson B, Schmitt A, Old M, Ozer E, Agrawal A, Schuller D, Teknos T, Kumar P. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status. Oncotarget. 2016 Apr 5;7(14):18665-77. PubMed PMID: 26919244

Choudhary M.M., France T.J., Teknos T.N. and Kumar P*. Interleukin-6 (IL-6) role in head and neck squamous cell carcinoma (HNSCC) progression. 2016, World Journal of Otorhinolaryngology - Head and Neck Surgery, In press

Jas C. Lang, PhD

McMullen K, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: A review. World J Otorhinolaryngology Head Neck Surg. 2016 Jun;2(2): 109-116

Jatana KR, Balasubramanian P, McMullen K, Lang JC, Teknos TN, Chalmers JJ. Effect of surgical intervention on detection of circulating tumor cells in squamous cell carcinoma of head and neck. Head and Neck. 2016 June 5. PubMed PMID: 27265898

Quintin Pan, PhD

Piao L, Mukherjee S, Chang Q, Xie X, Li H, Castellanos MR, Banerjee P, Iqbal H, Ivancic R, Wang X, and Pan Q (2016) TriCurin, a novel formulation of curcumin, resveratrol, and epicatechin gallate, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget. 2016 Jul;16. PubMed PMID: 27437871

Iqbal H and Pan Q (2016) Role of capecitabine in treating head and neck cancer. Expert Opin. Investig. Drugs. Expert Opin Investig Drugs. 2016 Jul;25(7):851-9. PubMed PMID: 27144283

Iqbal H and Pan Q (2016) Image guided surgery in the management of head and neck cancer. Oral Oncol. 2016 Jun;57:32-9. PubMed PMID: 27206842

Datta J, Islam M, Dutta S, Roy S, Pan Q, and Teknos TN (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol. 2016 May;56:32-39. PubMed PMID: 27086484

Kumar B, Cipolla M, Brown N, Kang SY, Dziegielewski PT, Durmus K, Ozer E, Old MO, Agrawal A, Carrau RL, Schuller DE, Leon M, Pan Q, Kumar P, Wood V, Burgers J, Wakely P, and Teknos TN. Surgical management of oropharyngeal squamous cell carcinoma: survival and functional outcomes. Head Neck. 2016 Apr;38 Suppl 1:E1794-802. PubMed PMID: 26694981

Castellanos MR and Pan Q (2016) Drugs targeting p53 in head and neck cancers. World J. Otolaryngol. In Press
Our Head and Neck Research Team

Our Head and Neck Research Team

Additional Research Members

  • Edmund Mroz, PhD, Research Associate Professor
  • Bhavna Kumar, MS, Program Director
  • Gaila Sunkle, MEd, Program Manager
  • Jharna Datta, PhD, Research Associate 2-B/H
  • Bin Li PhD, Research Associate 2-B/H
  • Longzhu Piao, PhD, Research Associate 2-B/H
  • Xueqian Wang, PhD, Research Associate 2-B/H
  • Xiujie Xie, PhD, Research Associate 2-B/H
  • Arti Yadav, MS, Research Assistant 2-B/H
  • Anita Janssen, BS, Research Associate 1-B/H
  • Satavisha Roy, BS, Research Associate 1-B/H
  • Jason Andersen, BS, Research Assistant 1-B/H